To include your compound in the COVID-19 Resource Center, submit it here.

Sphinx now faces a pipeline gap

Sphinx now faces a pipeline gap

Sphinx Pharmaceuticals Inc.'s decision to make major spending cuts should help rein in the company's burn rate and points to areas where cash-strapped biotech companies could make trims. But SPHX still has less than two years of cash and a pipeline of two products in early- to mid-stage

Read the full 542 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE